699 related articles for article (PubMed ID: 23565632)
1. Endothelial dysfunction and the effects of TNF inhibitors on the endothelium in psoriasis and psoriatic arthritis: a systematic review.
Brezinski EA; Follansbee MR; Armstrong EJ; Armstrong AW
Curr Pharm Des; 2014; 20(4):513-28. PubMed ID: 23565632
[TBL] [Abstract][Full Text] [Related]
2. Effects of biologic agents and other disease-modifying antirheumatic drugs on cardiovascular outcomes in psoriasis and psoriatic arthritis: a systematic review.
Armstrong AW; Brezinski EA; Follansbee MR; Armstrong EJ
Curr Pharm Des; 2014; 20(4):500-12. PubMed ID: 23565631
[TBL] [Abstract][Full Text] [Related]
3. Costs of tumor necrosis factor blockers per treated patient using real-world drug data in a managed care population.
Schabert VF; Watson C; Joseph GJ; Iversen P; Burudpakdee C; Harrison DJ
J Manag Care Pharm; 2013 Oct; 19(8):621-30. PubMed ID: 24074008
[TBL] [Abstract][Full Text] [Related]
4. TNF alpha inhibitors in the treatment of psoriasis and psoriatic arthritis.
Tobin AM; Kirby B
BioDrugs; 2005; 19(1):47-57. PubMed ID: 15691217
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of subcutaneous anti-tumor necrosis factor-alpha agents, etanercept and adalimumab, in elderly patients affected by psoriasis and psoriatic arthritis: an observational long-term study.
Esposito M; Giunta A; Mazzotta A; Zangrilli A; Babino G; Bavetta M; Perricone R; Chimenti S; Chimenti MS
Dermatology; 2012; 225(4):312-9. PubMed ID: 23295383
[TBL] [Abstract][Full Text] [Related]
6. [Biological agents in treatment of psoriatic arthritis].
Lewicki M; Dutkiewicz B; Widuchowska M; Kucharz EJ
Pol Merkur Lekarski; 2008 Jul; 25(145):97-100. PubMed ID: 18839626
[TBL] [Abstract][Full Text] [Related]
7. Psoriatic arthritis.
Goupille P
Joint Bone Spine; 2005 Dec; 72(6):466-70. PubMed ID: 16310398
[TBL] [Abstract][Full Text] [Related]
8. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis.
Collamer AN; Battafarano DF
Semin Arthritis Rheum; 2010 Dec; 40(3):233-40. PubMed ID: 20580412
[TBL] [Abstract][Full Text] [Related]
9. Off-label dermatologic uses of anti-TNF-a therapies.
Alexis AF; Strober BE
J Cutan Med Surg; 2005 Dec; 9(6):296-302. PubMed ID: 16699906
[TBL] [Abstract][Full Text] [Related]
10. Adverse reactions during biological drug therapy in psoriasis:clinical series and a review of the literature.
Montesu MA; Addis GM; Satta R; Cottoni F
G Ital Dermatol Venereol; 2011 Aug; 146(4):273-81. PubMed ID: 21785393
[TBL] [Abstract][Full Text] [Related]
11. Tumour necrosis factor (TNF) in psoriatic arthritis: pathophysiology and treatment with TNF inhibitors.
Mease PJ
Ann Rheum Dis; 2002 Apr; 61(4):298-304. PubMed ID: 11874829
[TBL] [Abstract][Full Text] [Related]
12. The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: a systematic review and meta-analysis of randomized controlled trials.
Dommasch ED; Abuabara K; Shin DB; Nguyen J; Troxel AB; Gelfand JM
J Am Acad Dermatol; 2011 Jun; 64(6):1035-50. PubMed ID: 21315483
[TBL] [Abstract][Full Text] [Related]
13. Risks and benefits of tumor necrosis factor-alpha inhibitors in the management of psoriatic arthritis: systematic review and metaanalysis of randomized controlled trials.
Saad AA; Symmons DP; Noyce PR; Ashcroft DM
J Rheumatol; 2008 May; 35(5):883-90. PubMed ID: 18381787
[TBL] [Abstract][Full Text] [Related]
14. Potential of tumor necrosis factor inhibitors in psoriasis and psoriatic arthritis.
Krueger G; Callis K
Arch Dermatol; 2004 Feb; 140(2):218-25. PubMed ID: 14967799
[TBL] [Abstract][Full Text] [Related]
15. TNFalpha therapy in psoriatic arthritis and psoriasis.
Mease P
Ann Rheum Dis; 2004 Jul; 63(7):755-8. PubMed ID: 15194567
[No Abstract] [Full Text] [Related]
16. Newly available treatments for psoriatic arthritis and their impact on skin psoriasis.
Galadari H; Fuchs B; Lebwohl M
Int J Dermatol; 2003 Mar; 42(3):231-7. PubMed ID: 12653923
[TBL] [Abstract][Full Text] [Related]
17. [Anti-TNF alpha in the treatment of psoriatic arthritis].
Claudepierre P; Wendling D; Cohen JD
Presse Med; 2006 Apr; 35(4 Pt 2):647-55. PubMed ID: 16614610
[TBL] [Abstract][Full Text] [Related]
18. Cytokine blockers in psoriatic arthritis.
Mease PJ
Ann Rheum Dis; 2001 Nov; 60 Suppl 3(Suppl 3):iii37-40. PubMed ID: 11890650
[TBL] [Abstract][Full Text] [Related]
19. Treatment of psoriatic arthritis and recalcitrant skin disease with combination therapy.
Hamilton TK
J Drugs Dermatol; 2008 Nov; 7(11):1089-93. PubMed ID: 19110745
[TBL] [Abstract][Full Text] [Related]
20. [Biological treatment of psoriasis and psoriatic arthritis].
Kragballe K; Deleuran B
Ugeskr Laeger; 2008 Jun; 170(24):2148-50. PubMed ID: 18565300
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
